NCT03824691

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 122 (estimated)
• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Detailed description

an open-label, single-centre, phase 2,

Conditions

• Bladder Carcinoma

Interventions

Type	Name	Description
DRUG	Cabozantinib	cabozantinib 40 mg orally once daily
DRUG	Durvalumab	1500 mg durvalumab (MEDI4736) IV infusion every 28 days

Timeline

• Start date: 2019-09-25
• Primary completion: 2023-02-01
• Completion: 2023-02-01
• First posted: 2019-01-31
• Last updated: 2021-02-25

Locations

1 site across 1 country: Italy